Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is expected to see growth in their key products, Verzenio and Jardiance, for cancer and cardiometabolic diseases. Their strong financials, with estimated product sales of $120M and an increase in their global POS, make them well-positioned to outperform their competitors. Additionally, with a focus on diversity and inclusivity in clinical trials and a strong development pipeline, their long-term outlook remains promising.

Bears say

Eli Lilly is facing several challenges that could have a negative impact on its stock performance. In particular, the company's recent earnings report showed a lower than expected revenue and earnings per share, and there are concerns about the company's pricing dynamics, competition, and pricing pressures from payors and regulators. Additionally, there are potential risks related to the company's pipeline, including negative trial results and competition from novel therapies. Furthermore, LLY's high valuation could face pressure in the face of concerning newsflow and challenges such as decreasing pharmacy reimbursement and uncertain utilization.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,302.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,302.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.